MD Anderson Partners with Takeda to Develop CAR Natural Killer-Cell Therapy
November 7th 2019The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited have entered an exclusive license agreement and research agreement to develop and market chimeric antigen receptor-directed natural killer-cell therapies.